As a first-time investor, it can be daunting trying to figure out where to put your money. But don’t worry, we’ve got you covered. Join us as we cover different types of investments!

What are the most popular types of investments? | Get Rich Slow Club

Whilst none of us are the next Warren Buffett, we have the ability to "own a piece of America", as he often suggests. For this reason, we're sharing the 10 most most popular US stocks on Pearler. 

Check out Pearler's most popular US stocks

Think of community data as a compass: you can choose any stock you want, but our community keeps pointing in the same general direction - simple, diversified, and cheap ETFs. Let's take a look at the 10 most popular ETFs on Pearler.

These are Pearler's most popular ETFs

Adaptive Biotechnologies Corp (ADPT:US) Share Price | Pearler

IVV.AX was created on 2000-05-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

The iShares S&P 500 ETF seeks to track the investment results of an index composed of large-capitalisation U.S. equities.

iShares S&P 500 Etf

VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

Vanguard Australian Shares Index ETF (ASX: VAS) seeks to track the performance of the ASX 300 index before account fees, expenses, and taxes. The index tracks the top 300 companies on the Australian Securities Exchange (ASX). These are mostly large and established Australian companies. It is a popular choice among passive individual investors who don't have the time or the expertise to actively invest in stocks.

Vanguard Australian Shares Index Etf

Autodesk, Inc. is engaged in three-dimensional (3D) design, engineering and entertainment technology solutions, spanning architecture, engineering, construction, product design, manufacturing, media and entertainment. Its product offerings are focused on four primary product families: Architecture, Engineering and Construction, AutoCAD and AutoCAD LT, Manufacturing, and Media and Entertainment. Its products include AutoCAD Civil 3D; Building Connected; Architecture, Engineering and Construction Collection; Autodesk Build; Revit; AutoCAD; AutoCAD LT; Computer-Aided Manufacturing (CAM) Solutions; Fusion 360; Product Design and Manufacturing Collection; Inventor; Vault; Media and Entertainment Collection; Maya; ShotGrid, and 3ds Max. Its product development and manufacturing software provides manufacturers in automotive, transportation, industrial machinery, consumer products, and building product industries with digital design, engineering, manufacturing, and production solutions. 

Autodesk, Inc.

Automatic Data Processing, Inc. (ADP) is a global technology company engaged in providing cloud-based human capital management (HCM) solutions that unite HR, payroll, talent, time, tax and benefits administration. Its segments include Employer Services and Professional Employer Organization (PEO). Its Employer Services segment serves clients ranging from single-employee small businesses to large enterprises with tens of thousands of employees around the world, offering a range of technology-based HCM solutions, including its cloud-based platforms, and human resource outsourcing (HRO) solutions (other than PEO) solutions. Its offerings include Payroll Services, Benefits Administration, Talent Management, HR Management, Workforce Management, Compliance Services, Insurance Services and Retirement Services. Its PEO business, called ADP TotalSource, provides clients with employment administration outsourcing solutions. It serves over 990,000 clients in 140 countries and territories.

Automatic Data Processing, Inc.

Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on using the biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine (IM) platform combines a suite of chemistry, computational biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. Its clinical diagnostic product, clonoSEQ, is used for the detection and monitoring minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL). The IM business consists of two areas: IM Pharma Services and Drug Discovery. Its immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA).

Adaptive Biotechnologies Corp

Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. The Company’s portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address significant unmet needs in CNS disorders and rare diseases. The Company’s pipeline includes NUPLAZID, Trofinetide, ACP-204 and Antisense Oligonucleotide (ASO) Programs. Its NUPLAZID is a treatment for Parkinson’s Disease Psychosis. Trofinetide is a treatment for Rett Syndrome. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. Its ACP-204 is a treatment for Alzheimer’s Disease Psychosis.

ACADIA Pharmaceuticals Inc.

Adobe Inc. is a software company that offers a line of products and services used by professionals, communicators, businesses, and consumers for creating, managing, delivering, measuring, optimizing, engaging and transacting with content and experiences across various digital media formats. The Company’s segments include Digital Media, Digital Experience and Publishing and Advertising. Digital Media segment provides products, services and solutions that enable individuals, teams and enterprises to create, publish and promote their content anywhere. Digital Media segment is centered around Adobe Creative Cloud and Adobe Document Cloud. Digital Experience segment provides an integrated platform and set of applications and services through Adobe Experience Cloud that enable brands and businesses to create, manage, execute, measure, monetize and optimize customer experiences. The Publishing and Advertising segment consists of products and services that address diverse market opportunities.

Adobe Systems Inc.

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is its nafamostat formulation for direct intravenous (IV) infusion being explored as an investigational product for the antiviral treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. Its pre-filled syringe product candidates include Fedsyra and Phenylephrine.

AcelRx Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of a- and b-thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD and anemia associated with low-to intermediate-risk myelodysplastic syndrome (LR MDS), and hemolytic anemias.

Agios Pharmaceuticals, Inc.

908 Devices Inc. offers a suite of purpose-built handheld and desktop mass spectrometry (Mass Spec) devices for the point of need. The Company's Mass Spec devices are used at the point of need to interrogate unknown and invisible materials and provide answers to address problems in life sciences research, bioprocessing, industrial biotechnology, forensics and adjacent markets. Its products include MX908 and Rebel. MX908 is a handheld, battery-powered, Mass Spec device designed for the analysis of solid, liquid, vapor and aerosol materials of unknown identity. MX908 is a multi-purpose device utilized by a spectrum of user segments for a variety of forensic field applications, including chemical, explosive, priority drug and hazardous materials operations, detecting materials at the trace level. The Rebel is a small desktop analyzer providing real-time information on the extracellular environment in bioprocesses.

ADPT

Buy

👑 Overview

📈

N/A

Annual Growth

🌏

0

Pearlers Invested

Key information

🔎 Fund Overview

Price History*

Unsure how much or often to invest?

🗓️ Investing frequency calculator

💵 Investing amount calculator

⏱️ Investing duration calculator

💵

6.50 AUD*

Purchase Fee

💼

N/A

Management Fee

💸

Want to know the long term costs?

Calculate the historic long term costs to hold your investments

Technical Info

$6.91

How our community is investing

0

N/A

N/A

N/A

N/A

ADPT investor breakdown

💵 Income of investors

👶 Age of investors

🙋 Legal gender of investors

$24.78 USD

Find Out More

$415.39 USD

Find Out More

$1.12 USD

Find Out More

$25.82 USD

Find Out More

$9.11 USD

Find Out More

$198.90 USD

Find Out More

$212.48 USD

Find Out More

Buy